Quote: Our best estimate for approval of Remestemcel is mid August 2024. The planned adult study in GvHD has for the moment been postponed pending the outcome of the resubmitted BLA. Valuation is increased from $0.58 to $1.40 reflecting significant changes to revenue forecasts bought about by renewed confidence for a prospective approval for Remestemcel in Paediatric GvHD later this year. A first approval may represent a gateway to a series of label expansions in the ensuing period as reflected in the share price movement in recent days. :End quote.
Aloha.
banter and General Discussion, page-9699
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.008(0.52%) |
Mkt cap ! $1.627B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $3.620M | 2.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 61373 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 17293 | 14 |
View Market Depth
| Last trade - 15.49pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |